Interest of the sentinel node in the case of infiltrating T1 luminal a breast carcinoma: retrospective study at the gynaecology department of the Francois Quesnay Mante-La-Jolie hospital, France

Kassé Raou; Kakou Charles; Yeo Kinifo; Boussou Chrisostome; Yao Alexis; Ouattara Issa; Boni Serge; Bakar Joseph

doi:10.18203/2320-1770.ijrcog20242783

Authors

Kassé Raou Obstetrics and Gynecology Department, Cocody University Hospital, Abidjan, Côte d'Ivoire
Kakou Charles Obstetrics and Gynecology Department, Cocody University Hospital, Abidjan, Côte d'Ivoire https://orcid.org/0000-0003-0639-8411
Yeo Kinifo Obstetrics and Gynecology Department, Cocody University Hospital, Abidjan, Côte d'Ivoire
Boussou Chrisostome Obstetrics and Gynecology Department, Cocody University Hospital, Abidjan, Côte d'Ivoire
Yao Alexis Obstetrics and Gynecology Department, Cocody University Hospital, Abidjan, Côte d'Ivoire
Ouattara Issa Obstetrics and Gynecology Department, Cocody University Hospital, Abidjan, Côte d'Ivoire
Boni Serge Obstetrics and Gynecology Department, Cocody University Hospital, Abidjan, Côte d'Ivoire
Bakar Joseph Obstetrics and Gynecology Department, Francois Quesnay Hospital, Mante-La-Jolie, France

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20242783

Keywords:

Breast cancer, Luminal A, Sentinel lymph node, Surgical excision

Abstract

Background: During these last twenty years, technic of sentinel lymph node (SLN) stayed the gold standard for axillary exploration, an alternative to axillary dissection in the surgical management of breast cancer. Objective of the study was to make an inventory of the technic of the sentinel lymph node technique in forms T1 Luminal A breast cancers.

Methods: It was a retrospective, descriptive and analytical study over a period of one year (March 2022 to March 2023) in the Gynecology department, François Quesnay hospital, in Mantes-La Jolie (France). Out of 103 files studied, we included 50 patients who had undergone sentinel lymph node excision for T1 luminal A breast cancers with non-palpable and non-detectable lymph nodes on imaging. The parameters studied were epidemiological data, clinical data and paraclinical data. The Chi² test (α=5%) made it possible to compare the groups (p<0.05 and CI=95%).

Results: The sentinel lymph node excision rate was 48.5%. The median age was 59 years. The epidemiological profile was as follows: Postmenopausal patients (70%), with family history of breast cancer (36%). The circumstances of discovery were: The perception of a breast mass (94%) and the screening examination (34%). The histological lesions were infiltrating ductal carcinomas in 94% of cases and 60% located in the right breast. There were 12 (24%) lymph node metastatic lesions, including 5 macrometastases and 7 micrometastases. There was no link between metastatic involvement of sentinel lymph nodes and age, menopause, family history of breast cancer, concept of screening, histological type. The Chi square was respectively 0; 1.34; 0.05; 0.41; 1.01. There was a link when the cancer was located in the right breast (chi²=10.52 and p=0.001), [CI = (12.16-35.84)].

Conclusions: There was no link between metastatic involvement of sentinel lymph nodes and luminal histological type A, T1. Furthermore, there was a link between metastatic involvement of the sentinel lymph node and the right-sided location of breast cancer. Is this linked to the predominance of cancer in the right breast?

Metrics

Metrics Loading ...

References

World Health Organization. International Agency for Research on Cancer. Global Cancer Observatory. Cancer Today Globocan 2022. France (Metropolitan). Geneva: WHO 2022. Available at: https:// gco.iarc.who.int. Assessed on 15 March 2021.

Jankowski C, Fumet JD, Kaderbhai C, Peignaux K, Arnould L, Ladoire S, Coutant C. Management of localized invasive breast cancers: new challenges. EMC – Gynecology. 2021;36(3):1.

Bézu C, Coutant C, Antoine M, Moutafoff C, Guillo E, Daraï E et al. Feasibility of sentinel lymph nodes in invasive breast cancer in case of histological discovery of multifocality. Gynecology Obstetrics & Fertility. 2009;37 (7–8):604-10.

Loaec C, Classe J.M. New indications for the sentinel lymph node. 2017;75:7-9.

D'HALLUIN G. The sentinel lymph node in breast cancer in La Chirurgie Gynécologique et Mammaire de Charente. Available at: http://www.Chirurgie- gynecologie.fr/index.html. Assessed on 15 March 2021.

Classe JM, Campone M, Lefevre-Lacoeuille C. Breast cancer: Screening and management. Elsevier Masson. Paris; 2016:233.

Republic of France: National Cancer Institute. Lymph node excision. Available at: http:// www.e- cancer.fr/cancer-du-sein/chirurgie-tumorectomie-et- mastectomie-exerese-du-ganglion-sentinelle. Assessed on 15 March 2021.

Mosbah R., Raimond. E, Pelissier A, Hocedez. C, Graesslin O. Relevance of the sentinel node procedure in multifocal and multicentric breast cancers. Gynecology Obstetrics & Fertility. 2015;43(5):375-82.

El Fouhi M, Benider A, Zoewendbem K, Gaëtan A, Mesfioui A. Epidemiological and pathological profile of breast cancer at Ibn Rochd University Hospital, Casablanca, Morocco. PAMJ. 2020;37(41):1-10.

Engbang JP, Essome H, Mve KV, Simo G, Essam SDJ, Mouelle SA, et al. Breast cancer in Cameroon, histo-epidemiological profile: about 3044 cases. Pan African Medical Journal. 2015;21:242.

Pike Mc, Pearce CL, Wu AH. Prevention of cancers of the breast, endometrium and ovary. Oncogene. 2004;23(38):6379-91.

Sancho-Garnier H, Triboulet JPl Villet R, Rouëssé J. Report 19-07 Report on the evolution of “organized” screening programs for breast, colon and rectal, and cervical cancers in France. Bulletin of the National Academy of Medicine. 2019;203(8):641-52.

World Health Organization. Classification of Tumours of the Breast. Lyon: IARC; 2012.

Sahraoui G, Khanchel F Chelbi E. Anatomopathological profile of breast cancer in the Tunisian Cap Bon. Pan African Medical Journal. 2017;26:11.

Rouzier R, Hini JD b, Bonneau C. The sentinel lymph node concept: a revolution in the management of lymph node invasion, a review with a focus on breast cancer. Bull Acad Natl Med. 2022;206:479-84.

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. NCCN guidelines insights: breast cancer, version 1.2017. J Natl Compr Canc Netw. 2017;15:433-51.

Lyman GH Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017;35:561- 4.

Gnant M, Harbeck N, Thomssen C. St. Gallen/Vienna 2017: a brief summary of the consensus discussion about escalation and de-escalation of primary breast cancer treatment. Breast Care 2017;12:102-7.

Costaz H, Rouffiac M, Boulle D, Arnould L, Beltjens F, Desmoulins I, et al. Strategies for sentinel node positivity in breast cancer. Bull Cancer 2019.